Week 24 results from a Phase IIb trial of GNbAC1 in patients with relapsing remitting multiple sclerosis (CHANGE-MS; Clinical trial assessing the HERV-W Env antagonist GNbAC1 for Efficacy in MS)
MULTIPLE SCLEROSIS JOURNAL（2017）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要